Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Blood ; 130(12): 1430-1440, 2017 09 21.
Article in English | MEDLINE | ID: mdl-28694326

ABSTRACT

Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell. In early-stage disease, lesions are limited to the skin, but in later-stage disease, the tumor cells can escape into the blood, the lymph nodes, and at times the visceral organs. To clarify the genomic basis of CTCL, we performed genomic analysis of 220 CTCLs. Our analyses identify 55 putative driver genes, including 17 genes not previously implicated in CTCL. These novel mutations are predicted to affect chromatin (BCOR, KDM6A, SMARCB1, TRRAP), immune surveillance (CD58, RFXAP), MAPK signaling (MAP2K1, NF1), NF-κB signaling (PRKCB, CSNK1A1), PI-3-kinase signaling (PIK3R1, VAV1), RHOA/cytoskeleton remodeling (ARHGEF3), RNA splicing (U2AF1), T-cell receptor signaling (PTPRN2, RLTPR), and T-cell differentiation (RARA). Our analyses identify recurrent mutations in 4 genes not previously identified in cancer. These include CK1α (encoded by CSNK1A1) (p.S27F; p.S27C), PTPRN2 (p.G526E), RARA (p.G303S), and RLTPR (p.Q575E). Last, we functionally validate CSNK1A1 and RLTPR as putative oncogenes. RLTPR encodes a recently described scaffolding protein in the T-cell receptor signaling pathway. We show that RLTPR (p.Q575E) increases binding of RLTPR to downstream components of the NF-κB signaling pathway, selectively upregulates the NF-κB pathway in activated T cells, and ultimately augments T-cell-receptor-dependent production of interleukin 2 by 34-fold. Collectively, our analysis provides novel insights into CTCL pathogenesis and elucidates the landscape of potentially targetable gene mutations.


Subject(s)
Genomics , Lymphoma, T-Cell, Cutaneous/genetics , Microfilament Proteins/genetics , Amino Acid Sequence , Amino Acid Substitution/genetics , Base Sequence , Genome, Human , HEK293 Cells , Humans , Jurkat Cells , Microfilament Proteins/chemistry , Mutation/genetics , NF-kappa B/metabolism , Oncogenes , Receptors, Antigen, T-Cell/metabolism , Sequence Analysis, DNA , Signal Transduction/genetics , rhoA GTP-Binding Protein/genetics
2.
Drug Saf ; 40(3): 249-255, 2017 03.
Article in English | MEDLINE | ID: mdl-27943160

ABSTRACT

INTRODUCTION: Controversy exists about an association between angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), and thiazides (TZs) and the risk of malignant melanoma (MM), and non-melanoma skin cancer-basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). OBJECTIVE: The aim of this study was to determine if an association exists for ACEI, ARB, or TZ exposure and skin cancers. METHODS: This was a matched cohort study using a large electronic medical records repository, the Northwestern Medicine Enterprise Data Warehouse (NMEDW). The exposed population consisted of patients with a documented order for an ACEI, ARB, or TZ with no prior history of skin cancer. The control population consisted of matched patients without documented exposure to ACEI, ARB, or TZ and no previous skin cancer. Incident MM, BCC, or SCC diagnosis by ICD-9 codes was recorded. Odds ratios (ORs) were obtained by using logistic regression analyses. RESULTS: Among the 27,134 patients exposed to an ACEI, 87 MM, 533 BCC, and 182 SCC were detected. Among the 13,818 patients exposed to an ARB, 96 MM, 283 BCC, and 106 SCC were detected. Among the 15,166 patients exposed to a TZ, 99 MM, 262 BCC, and 130 SCC were detected. Significant associations using ORs from logistic regression were found for MM and TZs (OR 1.82; 95% confidence interval [CI] 1.01-3.82); BCC and ARBs (OR 2.86; 95% CI 2.13-3.83), ACEIs (OR 2.23; 95% CI 1.78-2.81) and TZs (OR 2.11; 95% CI 1.60-2.79); SCC and ARBs (OR 2.22; 95% CI 1.37-3.61), ACEIs (OR 1.94; 95% CI 1.37-2.76), and TZs (OR 4.11; 95% CI 2.66-6.35). CONCLUSIONS: A safety signal for ACEIs, ARBs, and TZs and BCC and SCC, as well as for TZs and MM, was detected. An increased awareness and education, especially for those who are at high risk for skin cancer, are warranted for patients and healthcare providers. Further exploration of such associations for these commonly used drug classes is warranted.


Subject(s)
Angiotensin Receptor Antagonists/adverse effects , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Skin Neoplasms/etiology , Thiazides/adverse effects , Aged , Aged, 80 and over , Angiotensin Receptor Antagonists/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/etiology , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/etiology , Cohort Studies , Electronic Health Records , Female , Humans , Logistic Models , Male , Melanoma/epidemiology , Melanoma/etiology , Middle Aged , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Thiazides/administration & dosage
3.
Nat Genet ; 47(12): 1465-70, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26551667

ABSTRACT

Sézary syndrome is a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the malignant transformation of skin-homing central memory CD4(+) T cells. Here we performed whole-exome sequencing of tumor-normal sample pairs from 25 patients with Sézary syndrome and 17 patients with other CTCLs. These analyses identified a distinctive pattern of somatic copy number alterations in Sézary syndrome, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors. Mutation analysis identified a broad spectrum of somatic mutations in key genes involved in epigenetic regulation (TET2, CREBBP, KMT2D (MLL2), KMT2C (MLL3), BRD9, SMARCA4 and CHD3) and signaling, including MAPK1, BRAF, CARD11 and PRKG1 mutations driving increased MAPK, NF-κB and NFAT activity upon T cell receptor stimulation. Collectively, our findings provide new insights into the genetics of Sézary syndrome and CTCL and support the development of personalized therapies targeting key oncogenically activated signaling pathways for the treatment of these diseases.


Subject(s)
Gene Expression Regulation, Neoplastic , Genetic Markers/genetics , Lymphoma, T-Cell, Cutaneous/genetics , Mutation/genetics , Sezary Syndrome/genetics , Skin Neoplasms/genetics , Case-Control Studies , Chromosome Deletion , DNA Mutational Analysis , Epigenesis, Genetic , Exome/genetics , Genetic Loci , Humans , Immunoblotting , Lymphoma, T-Cell, Cutaneous/metabolism , Lymphoma, T-Cell, Cutaneous/pathology , Risk Factors , Sezary Syndrome/metabolism , Sezary Syndrome/pathology , Signal Transduction , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
4.
Arch Dermatol ; 146(9): 1021-5, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20855704

ABSTRACT

BACKGROUND: Exogenous ochronosis presents as an acquired asymptomatic hyperpigmentation on photoexposed areas, predominantly over bony prominences, and is caused by the topical application of several skin-lightening agents. OBSERVATIONS: We describe a 63-year-old Hispanic woman who developed exogenous ochronosis lesions on her face after using topical bleaching creams containing hydroquinone, 2% to 3%, and oxybenzone, 2%, for several years. Dermoscopy revealed irregular brown-gray globular, annular, and arciform structures that corresponded to focal deposition of ochronotic pigment on the dermis. These deposits correlated with multiple banana-shaped nonrefractile structures seen using reflectance confocal microscopy. Histopathologic sections revealed the deposition of a banana-shaped, yellow to brown material in the papillary and middle dermis. Ultrastructural examination revealed an amorphous electron-dense material mostly located in the core of elastic fibers and also in smaller amounts in the interstitium with prominent degenerative changes in the elastic fibers. A good correlation was observed between the results of both noninvasive techniques and the diagnostic histologic features of this condition. CONCLUSIONS: We characterized by means of dermoscopy, reflectance confocal microscopy, and electronic microscopy a case of exogenous ochronosis. To our knowledge, this is the first description of reflectance confocal microscopic findings in this condition. Dermoscopy and reflectance confocal microscopy are proved to be useful noninvasive techniques for the diagnosis of this pigmentary disorder.


Subject(s)
Cosmetics/adverse effects , Facial Dermatoses/chemically induced , Facial Dermatoses/pathology , Hyperpigmentation/chemically induced , Hyperpigmentation/pathology , Ochronosis/chemically induced , Ochronosis/pathology , Benzophenones/adverse effects , Benzophenones/pharmacology , Biopsy, Needle , Dermoscopy/methods , Facial Dermatoses/physiopathology , Female , Follow-Up Studies , Humans , Hydroquinones/adverse effects , Hydroquinones/pharmacology , Hyperpigmentation/physiopathology , Immunohistochemistry , Microscopy, Confocal/methods , Middle Aged , Ochronosis/physiopathology , Risk Assessment , Severity of Illness Index , Skin/pathology , Skin/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL
...